160 related articles for article (PubMed ID: 16845256)
1. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.
Schneider DJ; Keating F; Sobel BE
Coron Artery Dis; 2006 Aug; 17(5):471-6. PubMed ID: 16845256
[TBL] [Abstract][Full Text] [Related]
2. Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.
Schneider DJ; Sobel BE
Coron Artery Dis; 2009 Mar; 20(2):175-8. PubMed ID: 19194284
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Maegdefessel L; Buerke M; Schubert S; Reindl I; Michel T; Hauroeder B; Carter JM; Peetz D; Werdan K; Schlitt A
Thromb Haemost; 2008 Oct; 100(4):693-8. PubMed ID: 18841294
[TBL] [Abstract][Full Text] [Related]
5. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Coron Artery Dis; 2005 Sep; 16(6):401-5. PubMed ID: 16118546
[TBL] [Abstract][Full Text] [Related]
6. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.
Aggarwal A; Sobel BE; Schneider DJ
J Thromb Thrombolysis; 2002 Jun; 13(3):161-5. PubMed ID: 12355033
[TBL] [Abstract][Full Text] [Related]
7. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study.
Lev EI; Patel R; Karim A; Kleiman A; Badimon JJ; Kleiman NS
Thromb Haemost; 2006 Mar; 95(3):441-6. PubMed ID: 16525571
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2006; 118(3):361-9. PubMed ID: 16139336
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M
Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
14. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
[TBL] [Abstract][Full Text] [Related]
15. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin.
Harding SA; Din JN; Sarma J; Josephs DH; Fox KA; Newby DE
Heart; 2006 Nov; 92(11):1635-8. PubMed ID: 16709700
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin.
Eslam RB; Reiter N; Kaider A; Eichinger S; Lang IM; Panzer S
Eur Heart J; 2009 Aug; 30(15):1831-6. PubMed ID: 19468011
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial.
Khanna V; Shahzad A; Thayalasamy K; Kemp I; Mars C; Cooper R; Roome C; Wilson K; Harris S; Stables R; Curzen N
Thromb Res; 2018 Dec; 172():36-43. PubMed ID: 30359789
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
